Pricing Log in Create free account
Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS
−624.8%
Free cash flow
−108.8%

Quarter to September 2026, against a year earlier

103.34 6.75 +6.99%
Market cap
$9.2B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Spyre Therapeutics, Inc. 10-K filed Feb 27, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed · accepted 4:02 PM ET · Document on sec.gov · Filing index

Red flags

  • Material weakness

    Spyre Therapeutics, Inc.’s 10-K reports a material weakness in internal control over financial reporting

    The material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time, and management has concluded, through testing, that these controls are operating effectively.

    10-K filed · The filing · sec.gov